ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1871

A High Cardiovascular Biomarker Panel Risk Score Is Associated with Increased 10-Year Risk of Cardiovascular Events and Death in SLE

Maureen A. McMahon1, Jennifer M. Grossman2, Lori Sahakian3, Christina Charles-Schoeman4, John Fitzgerald1, Mihaela Taylor4, Alan Gorn1, Eloise Olmos1, Daniel J. Wallace5, Bevra H Hahn1,4 and Brian Skaggs4, 1Division of Rheumatology, UCLA David Geffen School of Medicine, Los Angeles, CA, 2Div of Rheumatology, UCLA David Geffen School of Medicine, Los Angeles, CA, 3UCLA David Geffen School of Medicine, Los Angeles, CA, 4Rheumatology, UCLA David Geffen School of Medicine, Los Angeles, CA, 5Division of Rheumatology, Cedars Sinai Medical Center, Los Angeles, CA

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: atherosclerosis and biomarkers, Lupus

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, October 22, 2018

Title: 4M081 ACR Abstract: Edmond L. Dubois, MD Memorial Lecture: SLE–Clinical (1870–1874)

Session Type: ACR Concurrent Abstract Session

Session Time: 2:30PM-4:00PM

Background/Purpose: There is a well-documented increase in atherosclerosis (ATH) in SLE that is not fully explained by traditional risk factors. Several non-Framingham biomarkers, including pro-inflammatory HDL (piHDL), leptin, plasma soluble TNF-like weak inducer of apoptosis (sTWEAK), and homocysteine are individually associated with subclinical ATH in SLE. We previously demonstrated that these biomarkers, combined with clinical variables such as age and diabetes, create a risk profile we have called PREDICTS. The PREDICTS profile more accurately identified SLE patients at risk for future subclinical ATH progression than any one variable alone. We set out to determine whether a high-risk PREDICTS score could also identify patients at risk for future cardiovascular events.

Methods: 392 SLE patients participated in this longitudinal prospective cohort study. 205 patients were included in this analysis, based on availability of 10-year cardiac event and/or mortality data. piHDL was measured using a published cell-free assay. Leptin and sTWEAK were determined at baseline using ELISA (R&D Biosystems). Homocysteine was determined by radioimmunoassay in the clinical laboratory of an academic medical center. Cardiac events were defined as myocardial infarction, a positive stress test, angioplasty, or percutaneous coronary intervention. Cerebrovascular events were defined as stroke or documented TIA. We defined high-risk PREDICTS as ≥ 3 of identified predictors or diabetes + ≥ 1 predictor.

Results: 16.1% (33) of SLE patients experienced a cerebrovascular accident during the 10-year follow-up period. 8.3% (17) of subjects had a cardiac event. 8.3% (17) of subjects died. Patients with a high-risk PREDICTS score at cohort entry were significantly more likely to have a cerebrovascular event (19.1% vs. 7.0%, p=0.04), or a cardiac event (10.9% vs. 0%, p=0.012). In addition, a high-risk baseline PREDICTS score also was also more likely to be found in patients that suffered any cardiovascular event or death (34.4% vs. 7%, p<0.0001). In multivariate analysis, baseline high-risk PREDICTS associated with a 3.7-fold increased odds for death or cardiovascular event over 10 years (p=0.004). Hypertension at baseline also was associated with increased odds for death or cardiovascular event (OR=4.9, p=0.001). No association with death or cardiovascular events were observed with hyperlipidemia, baseline carotid plaque, gender, or tobacco use.

Conclusion: A high-risk PREDICTS score and a history of hypertension at cohort entry confer significantly increased odds for a cardiovascular event or death in SLE patients over a 10-year follow-up. Further studies are necessary to identify proactive treatment strategies to prevent cardiovascular morbidity and mortality in SLE.


Disclosure: M. A. McMahon, None; J. M. Grossman, None; L. Sahakian, None; C. Charles-Schoeman, Bristol Myers Squibb, AbbVie, Octapharma, and Pfizer, 2,Regeneron-Sanofi, Pfizer, Octapharma, Amgen, and Gilead, 5; J. Fitzgerald, None; M. Taylor, Celgene Corporation, 8,AbbVie Inc., 8; A. Gorn, None; E. Olmos, None; D. J. Wallace, Program Advisor to Lupus Foundation of America, 5; B. H. Hahn, Janssen Research & Development, LLC, 2; B. Skaggs, None.

To cite this abstract in AMA style:

McMahon MA, Grossman JM, Sahakian L, Charles-Schoeman C, Fitzgerald J, Taylor M, Gorn A, Olmos E, Wallace DJ, Hahn BH, Skaggs B. A High Cardiovascular Biomarker Panel Risk Score Is Associated with Increased 10-Year Risk of Cardiovascular Events and Death in SLE [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/a-high-cardiovascular-biomarker-panel-risk-score-is-associated-with-increased-10-year-risk-of-cardiovascular-events-and-death-in-sle/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/a-high-cardiovascular-biomarker-panel-risk-score-is-associated-with-increased-10-year-risk-of-cardiovascular-events-and-death-in-sle/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology